NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug
By Emilie Ruscoe ( February 2, 2021, 6:36 PM EST) -- Investors in biopharmaceutical company NewLink Genetics Corp. told a Manhattan federal judge that they'd reached a $13.5 million deal to settle their proposed securities class action accusing the company and its co-founders of misrepresenting details of a pancreatic cancer drug trial....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.